Sourced material

Research reports

One topic per file, generated on a plan and a cadence, superseded rather than overwritten. This is what the domain dossiers are synthesized from.

A research report is the sourced material a domain dossier is synthesized from — generated on a plan and a cadence, one topic per file. A report carries no confidence tags. Its bracketed markers say who might have an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has to be drafted onto a candidate as unverified and pass the Verifier or the Corroborator, like everything else.

canine equine distal limb wounds

Care pathway, site of service, and what is already in the room — canine equine distal limb wounds

canine-equine-distal-limb-wounds.care-pathway.care-pathway-overview2026-09-016 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — canine equine distal limb wounds

canine-equine-distal-limb-wounds.clinical-evidence.clinical-evidence-overview2026-09-016 sourcesquarterly

Condition, prevalence, incidence and trend direction — canine equine distal limb wounds

canine-equine-distal-limb-wounds.epidemiology.epidemiology-overview2026-09-016 sourcesannual

Reference products and why people stop using them — canine equine distal limb wounds

canine-equine-distal-limb-wounds.reference-products.reference-products-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — canine equine distal limb wounds

canine-equine-distal-limb-wounds.technology.technology-overview2026-09-0111 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — canine equine distal limb wounds

canine-equine-distal-limb-wounds.user-groups.user-groups-overview2026-09-017 sourcesquarterly

chronic subjective tinnitus neuromodulation

Care pathway, site of service, and what is already in the room — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.care-pathway.care-pathway-overview2026-09-0112 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.clinical-evidence.clinical-evidence-overview2026-09-0111 sourcesquarterly

Condition, prevalence, incidence and trend direction — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.epidemiology.epidemiology-overview2026-09-017 sourcesannual

Entrants, exits, funding, launches, recalls — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.market-players.market-players-overview2026-09-0111 sourcesmonthly

Reference products and why people stop using them — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.reference-products.reference-products-overview2026-09-0112 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.reimbursement.reimbursement-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.technology.technology-overview2026-09-0114 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — chronic subjective tinnitus neuromodulation

chronic-subjective-tinnitus-neuromodulation.user-groups.user-groups-overview2026-09-017 sourcesquarterly

ctdna mrd assay validation

Care pathway, site of service, and what is already in the room — ctdna mrd assay validation

ctdna-mrd-assay-validation.care-pathway.care-pathway-overview2026-09-0111 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — ctDNA MRD assay validation

ctdna-mrd-assay-validation.clinical-evidence.clinical-evidence-overview2026-09-019 sourcesquarterly

Condition, prevalence, incidence and trend direction — ctdna mrd assay validation

ctdna-mrd-assay-validation.epidemiology.epidemiology-overview2026-09-013 sourcesannual

Entrants, exits, funding, launches, recalls — ctdna mrd assay validation

ctdna-mrd-assay-validation.market-players.market-players-overview2026-09-0110 sourcesmonthly

Reference products and why people stop using them — ctDNA MRD assay validation

ctdna-mrd-assay-validation.reference-products.reference-products-overview2026-09-016 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — ctdna mrd assay validation

ctdna-mrd-assay-validation.reimbursement.reimbursement-overview2026-09-018 sourcesquarterly

What changed in ten years and what is newly possible or cheap — ctdna mrd assay validation

ctdna-mrd-assay-validation.technology.technology-overview2026-09-018 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — ctdna mrd assay validation

ctdna-mrd-assay-validation.user-groups.user-groups-overview2026-09-017 sourcesquarterly

feline ckd subcutaneous fluid therapy

Care pathway, site of service, and what is already in the room — feline ckd subcutaneous fluid therapy

feline-ckd-subcutaneous-fluid-therapy.care-pathway.care-pathway-overview2026-09-018 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — feline ckd subcutaneous fluid therapy

feline-ckd-subcutaneous-fluid-therapy.clinical-evidence.clinical-evidence-overview2026-09-017 sourcesquarterly

Condition, prevalence, incidence and trend direction — feline ckd subcutaneous fluid therapy

feline-ckd-subcutaneous-fluid-therapy.epidemiology.epidemiology-overview2026-09-016 sourcesannual

Reference products and why people stop using them — feline ckd subcutaneous fluid therapy

feline-ckd-subcutaneous-fluid-therapy.reference-products.reference-products-overview2026-09-017 sourcesquarterly

What changed in ten years and what is newly possible or cheap — feline CKD subcutaneous fluid therapy

feline-ckd-subcutaneous-fluid-therapy.technology.technology-overview2026-09-019 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — feline ckd subcutaneous fluid therapy

feline-ckd-subcutaneous-fluid-therapy.user-groups.user-groups-overview2026-09-018 sourcesquarterly

internal hemorrhoids office based treatment

Care pathway, site of service, and what is already in the room — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.care-pathway.care-pathway-overview2026-09-019 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.clinical-evidence.clinical-evidence-overview2026-09-0110 sourcesquarterly

Condition, prevalence, incidence and trend direction — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.epidemiology.epidemiology-overview2026-09-017 sourcesannual

Entrants, exits, funding, launches, recalls — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.market-players.market-players-overview2026-09-0115 sourcesmonthly

Reference products and why people stop using them — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.reference-products.reference-products-overview2026-09-0116 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.reimbursement.reimbursement-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.technology.technology-overview2026-09-0115 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — internal hemorrhoids office based treatment

internal-hemorrhoids-office-based-treatment.user-groups.user-groups-overview2026-09-018 sourcesquarterly

lower extremity lymphedema compression therapy

Care pathway, site of service, and what is already in the room — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.care-pathway.care-pathway-overview2026-09-0110 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.clinical-evidence.clinical-evidence-overview2026-09-019 sourcesquarterly

Condition, prevalence, incidence and trend direction — lower extremity lymphedema

lower-extremity-lymphedema-compression-therapy.epidemiology.epidemiology-overview2026-09-017 sourcesannual

Entrants, exits, funding, launches, recalls — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.market-players.market-players-overview2026-09-0114 sourcesmonthly

Reference products and why people stop using them — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.reference-products.reference-products-overview2026-09-0113 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.reimbursement.reimbursement-overview2026-09-0111 sourcesquarterly

What changed in ten years and what is newly possible or cheap — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.technology.technology-overview2026-09-0115 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — lower extremity lymphedema compression therapy

lower-extremity-lymphedema-compression-therapy.user-groups.user-groups-overview2026-09-0111 sourcesquarterly

neonatal hyperbilirubinemia home phototherapy

Care pathway, site of service, and what is already in the room — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.care-pathway.care-pathway-overview2026-09-018 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.clinical-evidence.clinical-evidence-overview2026-09-019 sourcesquarterly

Condition, prevalence, incidence and trend direction — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.epidemiology.epidemiology-overview2026-09-016 sourcesannual

Entrants, exits, funding, launches, recalls — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.market-players.market-players-overview2026-09-018 sourcesmonthly

Reference products and why people stop using them — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.reference-products.reference-products-overview2026-09-016 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.reimbursement.reimbursement-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.technology.technology-overview2026-09-0111 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — neonatal hyperbilirubinemia home phototherapy

neonatal-hyperbilirubinemia-home-phototherapy.user-groups.user-groups-overview2026-09-018 sourcesquarterly

pediatric obstructive sleep apnea testing

Care pathway, site of service, and what is already in the room — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.care-pathway.care-pathway-overview2026-09-017 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.clinical-evidence.clinical-evidence-overview2026-09-0110 sourcesquarterly

Condition, prevalence, incidence and trend direction — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.epidemiology.epidemiology-overview2026-09-018 sourcesannual

Entrants, exits, funding, launches, recalls — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.market-players.market-players-overview2026-09-0113 sourcesmonthly

Reference products and why people stop using them — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.reference-products.reference-products-overview2026-09-0111 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.reimbursement.reimbursement-overview2026-09-015 sourcesquarterly

What changed in ten years and what is newly possible or cheap — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.technology.technology-overview2026-09-0115 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — pediatric obstructive sleep apnea testing

pediatric-obstructive-sleep-apnea-testing.user-groups.user-groups-overview2026-09-0112 sourcesquarterly

pediatric persistent asthma home monitoring

Care pathway, site of service, and what is already in the room — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.care-pathway.care-pathway-overview2026-09-018 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.clinical-evidence.clinical-evidence-overview2026-09-017 sourcesquarterly

Condition, prevalence, incidence and trend direction — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.epidemiology.epidemiology-overview2026-09-016 sourcesannual

Entrants, exits, funding, launches, recalls — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.market-players.market-players-overview2026-09-0113 sourcesmonthly

Reference products and why people stop using them — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.reference-products.reference-products-overview2026-09-0110 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.reimbursement.reimbursement-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.technology.technology-overview2026-09-0113 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — pediatric persistent asthma home monitoring

pediatric-persistent-asthma-home-monitoring.user-groups.user-groups-overview2026-09-018 sourcesquarterly

potassium monitoring ckd

Care pathway, site of service, and what is already in the room — potassium monitoring ckd

potassium-monitoring-ckd.care-pathway.care-pathway-overview2026-09-019 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — potassium monitoring ckd

potassium-monitoring-ckd.clinical-evidence.clinical-evidence-overview2026-09-017 sourcesquarterly

Condition, prevalence, incidence and trend direction — CKD, heart failure and hyperkalemia in RAASi-monitored populations

potassium-monitoring-ckd.epidemiology.epidemiology-overview2026-09-016 sourcesannual

Market players in potassium and creatinine monitoring for RAASi titration — entrants, exits, funding, launches, recalls

potassium-monitoring-ckd.market-players.market-players-overview2026-09-0114 sourcesmonthly

Reference products for potassium and creatinine monitoring during RAASi titration — and why people stop using them

potassium-monitoring-ckd.reference-products.reference-products-overview2026-08-319 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — potassium monitoring ckd

potassium-monitoring-ckd.reimbursement.reimbursement-overview2026-09-019 sourcesquarterly

What changed in ten years and what is newly possible or cheap — potassium monitoring in CKD

potassium-monitoring-ckd.technology.technology-overview2026-09-018 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — potassium monitoring ckd

potassium-monitoring-ckd.user-groups.user-groups-overview2026-09-017 sourcesquarterly

stress urinary incontinence

Care pathway, site of service, and what is already in the room — stress urinary incontinence

stress-urinary-incontinence.care-pathway.care-pathway-overview2026-09-017 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — stress urinary incontinence

stress-urinary-incontinence.clinical-evidence.clinical-evidence-overview2026-09-019 sourcesquarterly

Condition, prevalence, incidence and trend direction — stress urinary incontinence

stress-urinary-incontinence.epidemiology.epidemiology-overview2026-09-019 sourcesannual

Entrants, exits, funding, launches, recalls — stress urinary incontinence

stress-urinary-incontinence.market-players.market-players-overview2026-09-0114 sourcesmonthly

Reference products and why people stop using them — stress urinary incontinence

stress-urinary-incontinence.reference-products.reference-products-overview2026-09-017 sourcesquarterly

Codes, payment rates, coverage policy, and whose budget it comes from — stress urinary incontinence

stress-urinary-incontinence.reimbursement.reimbursement-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — stress urinary incontinence

stress-urinary-incontinence.technology.technology-overview2026-09-019 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — stress urinary incontinence

stress-urinary-incontinence.user-groups.user-groups-overview2026-09-016 sourcesquarterly

veterinary diabetes glucose monitoring

Care pathway, site of service, and what is already in the room — veterinary diabetes glucose monitoring

veterinary-diabetes-glucose-monitoring.care-pathway.care-pathway-overview2026-09-0110 sourcesannual

Guideline position, pivotal evidence, effect sizes, negative findings — veterinary diabetes glucose monitoring

veterinary-diabetes-glucose-monitoring.clinical-evidence.clinical-evidence-overview2026-09-016 sourcesquarterly

Condition, prevalence, incidence and trend direction — veterinary diabetes glucose monitoring

veterinary-diabetes-glucose-monitoring.epidemiology.epidemiology-overview2026-09-0110 sourcesannual

Reference products and why people stop using them — veterinary diabetes glucose monitoring

veterinary-diabetes-glucose-monitoring.reference-products.reference-products-overview2026-09-016 sourcesquarterly

What changed in ten years and what is newly possible or cheap — veterinary diabetes glucose monitoring

veterinary-diabetes-glucose-monitoring.technology.technology-overview2026-09-018 sourcesannual

Prescriber, operator, purchaser, payer and patient — separate incentives — veterinary diabetes glucose monitoring

veterinary-diabetes-glucose-monitoring.user-groups.user-groups-overview2026-09-019 sourcesquarterly